# Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial

> **NCT05999604** · PHASE3 · RECRUITING · sponsor: **Fondation Ophtalmologique Adolphe de Rothschild** · enrollment: 244 (estimated)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Ocrelizumab Injection [Ocrevus]
- **DRUG:** Ocrelizumab Injection [Ocrevus]

## Key facts

- **NCT ID:** NCT05999604
- **Lead sponsor:** Fondation Ophtalmologique Adolphe de Rothschild
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-09
- **Primary completion:** 2029-11
- **Final completion:** 2029-11
- **Target enrollment:** 244 (ESTIMATED)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05999604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05999604, "Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05999604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*